Compare Recursion Pharmaceuticals Inc (RXRX) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Royal Bank of Canada — how do they compare? Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.14B), while Royal Bank of Canada trades at $192.67 (market cap $262.99B). The key difference: Royal Bank of Canada is far larger — about 122.9× Recursion Pharmaceuticals Inc's market cap, and Royal Bank of Canada pays a 2.66% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Royal Bank of Canada for 47 Days on average.
| RXRX | RY | |
|---|---|---|
Market Cap | $2.14B | $262.99B |
Volume | 30,789,535 | 1,016,377 |
Sector | Health | Financials |
52-Week High | $6.79 | $217.87 |
52-Week Low | $2.84 | $143.64 |
Typical Hold Time | 22 Days | 47 Days |
Enterprise Value | $1.66B | $730.11B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Royal Bank of Canada (RY) trades at $191.22, down 2.61% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.07 versus $2.89 expected, and robust profitability with a 32.01% net income margin. Revenue growth accelerated to $66.53B in 2025, and the company maintains a solid dividend, with recent payouts of $1.76 per share. Analyst sentiment is mixed, with a Buy consensus of 43% but technical indicators pointing to near-term pressure.
RY presents a value opportunity with a reasonable P/E of 17.2 and strong ROE of 17.2%, supported by earnings momentum and strategic initiatives like global transaction banking integration. Risks include stretched valuations relative to peers, a high EV/EBITDA of 23.52, and macroeconomic sensitivity. The stock's current price near support at $189 suggests potential stability, but investors should weigh fundamental strength against technical bearishness and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
